Robert Hazlett
Stock Analyst at BTIG
(0.83)
# 2,798
Out of 4,479 analysts
29
Total ratings
33.33%
Success rate
-17.24%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $3.87 | +261.76% | 2 | May 9, 2024 | |
| AURA Aura Biosciences | Maintains: Buy | $38 → $21 | $7.15 | +193.71% | 2 | Dec 8, 2023 | |
| SEEL Seelos Therapeutics | Maintains: Buy | $2,640 → $960 | $0.59 | +162,639.45% | 5 | May 15, 2023 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.28 | +7,042.86% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $78.93 | +24.16% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $2.94 | +1,944.29% | 2 | Oct 5, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Neutral | n/a | $1.17 | - | 1 | Mar 15, 2022 | |
| GRTX Galera Therapeutics | Upgrades: Buy | n/a | $0.14 | - | 2 | Dec 15, 2021 | |
| CMPS COMPASS Pathways | Initiates: Buy | n/a | $5.96 | - | 1 | May 27, 2021 | |
| TCON TRACON Pharmaceuticals | Upgrades: Buy | $280 | $0.95 | +29,373.68% | 2 | Apr 16, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | n/a | $20.39 | - | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | n/a | $68.54 | - | 1 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | n/a | $0.36 | - | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Initiates: Buy | n/a | $0.96 | - | 1 | Dec 7, 2017 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | n/a | $11.51 | - | 2 | Oct 16, 2017 |
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $3.87
Upside: +261.76%
Aura Biosciences
Dec 8, 2023
Maintains: Buy
Price Target: $38 → $21
Current: $7.15
Upside: +193.71%
Seelos Therapeutics
May 15, 2023
Maintains: Buy
Price Target: $2,640 → $960
Current: $0.59
Upside: +162,639.45%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.28
Upside: +7,042.86%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $78.93
Upside: +24.16%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $2.94
Upside: +1,944.29%
Nektar Therapeutics
Mar 15, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Galera Therapeutics
Dec 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $0.14
Upside: -
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $5.96
Upside: -
TRACON Pharmaceuticals
Apr 16, 2021
Upgrades: Buy
Price Target: $280
Current: $0.95
Upside: +29,373.68%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: n/a
Current: $20.39
Upside: -
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: n/a
Current: $68.54
Upside: -
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: n/a
Current: $0.36
Upside: -
Akebia Therapeutics
Dec 7, 2017
Initiates: Buy
Price Target: n/a
Current: $0.96
Upside: -
KalVista Pharmaceuticals
Oct 16, 2017
Maintains: Buy
Price Target: n/a
Current: $11.51
Upside: -